Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mucic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mucic Acid SCHEMBL20853833 | 0.93 | TSHR (0.56) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL5497 | 0.89 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL15895451 | 0.89 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL5901 | 0.89 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL77363 | 0.89 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL17594183 | 0.89 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL7224759 | 0.89 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL3514596 | 0.89 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL18871641 | 0.89 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL5312196 | 0.89 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091436-B2 | Process for the separation of optical isomers of racemic 3-alkylpiperidine-carboxylic acid ethyl esters | RICHTER GEDEON NYRT. (HU) | 2021-08-17 | — | — | US | claimed |
| US-20200131126-A1 | Process for the Separation of Optical Isomers of Racemic 3-Alkylpiperidine-Carboxylic Acid Ethyl Esters | RICHTER GEDEON NYRT. (HU) | 2020-04-30 | — | — | US | claimed |
| EP-0052719-B1 | PROCESS FOR THE SEPARATION OF METAL CATALYSTS, AND USE OF MEMBRANE SEPARATION APPARATUSES | MERCK PATENT GmbH (DE) | 1985-03-20 | — | — | EP | claimed |
| EP-0040709-B1 | PROCESS FOR THE PRODUCTION OF DIACETONE-KETO-GULONIC ACID | MERCK PATENT GmbH (DE) | 1984-07-04 | — | — | EP | claimed |
| US-4375393-A | Preparation of diacetone-ketogulonic acid | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-03-01 | — | — | US | claimed |
| US-4097346-A | Electrochemical oxidation of diacetone-L-sorbose to diacetone-L-ketogulonic acid | HOFFMANN-LA ROCHE INC. | 1978-06-27 | — | — | US | claimed |
| US-11091436-B2 | Process for the separation of optical isomers of racemic 3-alkylpiperidine-carboxylic acid ethyl esters | RICHTER GEDEON NYRT. (HU) | 2021-08-17 | — | — | US | disclosed |
| US-11091436-B2 | Process for the separation of optical isomers of racemic 3-alkylpiperidine-carboxylic acid ethyl esters | RICHTER GEDEON NYRT. (HU) | 2021-08-17 | — | — | US | disclosed |
| US-20200131126-A1 | Process for the Separation of Optical Isomers of Racemic 3-Alkylpiperidine-Carboxylic Acid Ethyl Esters | RICHTER GEDEON NYRT. (HU) | 2020-04-30 | — | — | US | disclosed |
| US-20200131126-A1 | Process for the Separation of Optical Isomers of Racemic 3-Alkylpiperidine-Carboxylic Acid Ethyl Esters | RICHTER GEDEON NYRT. (HU) | 2020-04-30 | — | — | US | disclosed |
| US-7696360-B2 | Method for the separation of ascorbic acid from a polar solvent containing ascorbic acid and 2-keto-L-gulonic acid | BASF AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| EP-1878762-A1 | Oxidisable polymer | DSMIP Assets B.V. (NL) | 2008-01-16 | — | — | EP | disclosed |
| US-20060149084-A1 | Method for extracting 2-ketone-l-gulonic acid from a polar, preferably aqueous solvent | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-06 | — | — | US | disclosed |
| US-4375393-A | Preparation of diacetone-ketogulonic acid | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-03-01 | — | — | US | disclosed |
| EP-0040709-A1 | Process for the production of diacetone-keto-gulonic acid | MERCK PATENT GmbH (DE) | 1981-12-02 | — | — | EP | disclosed |
| US-4097346-A | Electrochemical oxidation of diacetone-L-sorbose to diacetone-L-ketogulonic acid | HOFFMANN-LA ROCHE INC. | 1978-06-27 | — | — | US | disclosed |
| US-4097346-A | Electrochemical oxidation of diacetone-L-sorbose to diacetone-L-ketogulonic acid | HOFFMANN-LA ROCHE INC. | 1978-06-27 | — | — | US | disclosed |
| US-4097346-A | Electrochemical oxidation of diacetone-L-sorbose to diacetone-L-ketogulonic acid | HOFFMANN-LA ROCHE INC. | 1978-06-27 | — | — | US | disclosed |
| US-4040938-A | Electrode arrangement for electrochemical cells | HOFFMANN-LA ROCHE INC., A CORP OF NJ | 1977-08-09 | — | — | US | disclosed |
| US-4008132-A | Process for the electrolyte preparation of diacetone-2-ketogulonic acid | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149084-A1 | Method for extracting 2-ketone-l-gulonic acid from a polar, preferably aqueous solvent | GK, AK2, KHK | TSHR 4488/4885PDE4A 3724/4885CYP2C9 895/4885 |
| US-11091436-B2 | Process for the separation of optical isomers of racemic 3-alkylpiperidine-carboxylic acid ethyl esters | ARHGDIA, ALDH1A2, AKR1C3 | TSHR 4311/4885PDE4A 1131/4885CYP2C9 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.